nodes	percent_of_prediction	percent_of_DWPC	metapath
Diphenhydramine—atopic dermatitis—psoriasis	0.724	1	CtDrD
Diphenhydramine—CYP1A2—Clobetasol propionate—psoriasis	0.0369	0.194	CbGbCtD
Diphenhydramine—CYP2B6—Cholecalciferol—psoriasis	0.0219	0.115	CbGbCtD
Diphenhydramine—CYP1A2—Methoxsalen—psoriasis	0.0194	0.102	CbGbCtD
Diphenhydramine—CYP2D6—Hydroxyurea—psoriasis	0.0174	0.0918	CbGbCtD
Diphenhydramine—CYP2C19—Cholecalciferol—psoriasis	0.0139	0.0732	CbGbCtD
Diphenhydramine—CYP2C9—Cholecalciferol—psoriasis	0.0116	0.0608	CbGbCtD
Diphenhydramine—CYP2D6—Cholecalciferol—psoriasis	0.0106	0.0556	CbGbCtD
Diphenhydramine—CYP2C19—Prednisone—psoriasis	0.00964	0.0507	CbGbCtD
Diphenhydramine—CYP2B6—Dexamethasone—psoriasis	0.00947	0.0498	CbGbCtD
Diphenhydramine—CYP2C19—Cyclosporine—psoriasis	0.00914	0.0481	CbGbCtD
Diphenhydramine—CYP2C9—Cyclosporine—psoriasis	0.0076	0.04	CbGbCtD
Diphenhydramine—CYP2D6—Cyclosporine—psoriasis	0.00695	0.0366	CbGbCtD
Diphenhydramine—CYP2C19—Dexamethasone—psoriasis	0.00602	0.0317	CbGbCtD
Diphenhydramine—CYP2C9—Dexamethasone—psoriasis	0.005	0.0263	CbGbCtD
Diphenhydramine—CYP2D6—Dexamethasone—psoriasis	0.00457	0.0241	CbGbCtD
Diphenhydramine—CYP2C18—Xenobiotics—CYP2S1—psoriasis	0.00112	0.0661	CbGpPWpGaD
Diphenhydramine—CYP2B6—CYP2E1 reactions—CYP2S1—psoriasis	0.00089	0.0525	CbGpPWpGaD
Diphenhydramine—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.000673	0.0396	CbGpPWpGaD
Diphenhydramine—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.000619	0.0365	CbGpPWpGaD
Diphenhydramine—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.000613	0.0361	CbGpPWpGaD
Diphenhydramine—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.000577	0.034	CbGpPWpGaD
Diphenhydramine—CYP2B6—Xenobiotics—CYP2S1—psoriasis	0.000552	0.0325	CbGpPWpGaD
Diphenhydramine—CYP2C18—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000466	0.0275	CbGpPWpGaD
Diphenhydramine—CYP2C18—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00046	0.0271	CbGpPWpGaD
Diphenhydramine—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000417	0.0246	CbGpPWpGaD
Diphenhydramine—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000384	0.0226	CbGpPWpGaD
Diphenhydramine—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.00038	0.0224	CbGpPWpGaD
Diphenhydramine—CYP2C18—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000378	0.0223	CbGpPWpGaD
Diphenhydramine—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000325	0.0191	CbGpPWpGaD
Diphenhydramine—PTGS1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000243	0.0143	CbGpPWpGaD
Diphenhydramine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000229	0.0135	CbGpPWpGaD
Diphenhydramine—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000226	0.0133	CbGpPWpGaD
Diphenhydramine—CYP2C18—Biological oxidations—CYP2S1—psoriasis	0.000201	0.0118	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metapathway biotransformation—CYP2S1—psoriasis	0.000198	0.0117	CbGpPWpGaD
Diphenhydramine—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000186	0.0109	CbGpPWpGaD
Diphenhydramine—PTGS1—Overview of nanoparticle effects—CRP—psoriasis	0.00018	0.0106	CbGpPWpGaD
Diphenhydramine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000173	0.0102	CbGpPWpGaD
Diphenhydramine—CYP2C18—Tryptophan metabolism—CAT—psoriasis	0.000173	0.0102	CbGpPWpGaD
Diphenhydramine—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000171	0.0101	CbGpPWpGaD
Diphenhydramine—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000171	0.0101	CbGpPWpGaD
Diphenhydramine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000159	0.00938	CbGpPWpGaD
Diphenhydramine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000158	0.0093	CbGpPWpGaD
Diphenhydramine—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000157	0.00926	CbGpPWpGaD
Diphenhydramine—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000156	0.00918	CbGpPWpGaD
Diphenhydramine—Vomiting—Acitretin—psoriasis	0.000152	0.00222	CcSEcCtD
Diphenhydramine—Hyperhidrosis—Mycophenolic acid—psoriasis	0.000152	0.00222	CcSEcCtD
Diphenhydramine—Vomiting—Fluocinolone Acetonide—psoriasis	0.000152	0.00221	CcSEcCtD
Diphenhydramine—Nervousness—Cyclosporine—psoriasis	0.000152	0.00221	CcSEcCtD
Diphenhydramine—Rash—Acitretin—psoriasis	0.000151	0.0022	CcSEcCtD
Diphenhydramine—Dermatitis—Acitretin—psoriasis	0.000151	0.0022	CcSEcCtD
Diphenhydramine—Rash—Fluocinolone Acetonide—psoriasis	0.000151	0.00219	CcSEcCtD
Diphenhydramine—Dermatitis—Fluocinolone Acetonide—psoriasis	0.00015	0.00219	CcSEcCtD
Diphenhydramine—Anorexia—Mycophenolic acid—psoriasis	0.00015	0.00219	CcSEcCtD
Diphenhydramine—Headache—Acitretin—psoriasis	0.00015	0.00219	CcSEcCtD
Diphenhydramine—Headache—Fluocinolone Acetonide—psoriasis	0.00015	0.00218	CcSEcCtD
Diphenhydramine—Tension—Mycophenolate mofetil—psoriasis	0.000149	0.00218	CcSEcCtD
Diphenhydramine—Neuropathy peripheral—Betamethasone—psoriasis	0.000149	0.00217	CcSEcCtD
Diphenhydramine—Neuropathy peripheral—Dexamethasone—psoriasis	0.000149	0.00217	CcSEcCtD
Diphenhydramine—Nervousness—Mycophenolate mofetil—psoriasis	0.000148	0.00216	CcSEcCtD
Diphenhydramine—Hypotension—Mycophenolic acid—psoriasis	0.000147	0.00215	CcSEcCtD
Diphenhydramine—Vision blurred—Cyclosporine—psoriasis	0.000147	0.00214	CcSEcCtD
Diphenhydramine—Tremor—Cyclosporine—psoriasis	0.000146	0.00213	CcSEcCtD
Diphenhydramine—Sweating increased—Prednisone—psoriasis	0.000144	0.0021	CcSEcCtD
Diphenhydramine—Agitation—Cyclosporine—psoriasis	0.000143	0.00209	CcSEcCtD
Diphenhydramine—Tremor—Mycophenolate mofetil—psoriasis	0.000143	0.00208	CcSEcCtD
Diphenhydramine—Insomnia—Mycophenolic acid—psoriasis	0.000142	0.00208	CcSEcCtD
Diphenhydramine—Nausea—Acitretin—psoriasis	0.000142	0.00207	CcSEcCtD
Diphenhydramine—Nausea—Fluocinolone Acetonide—psoriasis	0.000142	0.00207	CcSEcCtD
Diphenhydramine—Paraesthesia—Mycophenolic acid—psoriasis	0.000141	0.00206	CcSEcCtD
Diphenhydramine—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00014	0.00827	CbGpPWpGaD
Diphenhydramine—Vertigo—Cyclosporine—psoriasis	0.00014	0.00204	CcSEcCtD
Diphenhydramine—Somnolence—Mycophenolic acid—psoriasis	0.00014	0.00204	CcSEcCtD
Diphenhydramine—Agitation—Mycophenolate mofetil—psoriasis	0.00014	0.00204	CcSEcCtD
Diphenhydramine—Dyspepsia—Mycophenolic acid—psoriasis	0.000139	0.00202	CcSEcCtD
Diphenhydramine—Decreased appetite—Mycophenolic acid—psoriasis	0.000137	0.002	CcSEcCtD
Diphenhydramine—Vertigo—Mycophenolate mofetil—psoriasis	0.000137	0.00199	CcSEcCtD
Diphenhydramine—Irritability—Methotrexate—psoriasis	0.000137	0.00199	CcSEcCtD
Diphenhydramine—Fatigue—Mycophenolic acid—psoriasis	0.000136	0.00198	CcSEcCtD
Diphenhydramine—Convulsion—Cyclosporine—psoriasis	0.000135	0.00197	CcSEcCtD
Diphenhydramine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000135	0.00795	CbGpPWpGaD
Diphenhydramine—Asthenia—Hydroxyurea—psoriasis	0.000135	0.00197	CcSEcCtD
Diphenhydramine—Constipation—Mycophenolic acid—psoriasis	0.000135	0.00196	CcSEcCtD
Diphenhydramine—Palpitations—Mycophenolate mofetil—psoriasis	0.000135	0.00196	CcSEcCtD
Diphenhydramine—Vision blurred—Prednisolone—psoriasis	0.000134	0.00195	CcSEcCtD
Diphenhydramine—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000133	0.00785	CbGpPWpGaD
Diphenhydramine—Convulsion—Mycophenolate mofetil—psoriasis	0.000132	0.00192	CcSEcCtD
Diphenhydramine—Dry mouth—Cyclosporine—psoriasis	0.00013	0.00189	CcSEcCtD
Diphenhydramine—Feeling abnormal—Mycophenolic acid—psoriasis	0.00013	0.00189	CcSEcCtD
Diphenhydramine—Neuropathy peripheral—Prednisone—psoriasis	0.000129	0.00189	CcSEcCtD
Diphenhydramine—PTGS1—Biological oxidations—CYP2S1—psoriasis	0.000129	0.00762	CbGpPWpGaD
Diphenhydramine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000129	0.00761	CbGpPWpGaD
Diphenhydramine—Diarrhoea—Hydroxyurea—psoriasis	0.000129	0.00188	CcSEcCtD
Diphenhydramine—Confusional state—Cyclosporine—psoriasis	0.000128	0.00187	CcSEcCtD
Diphenhydramine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000128	0.00754	CbGpPWpGaD
Diphenhydramine—Vertigo—Prednisolone—psoriasis	0.000128	0.00186	CcSEcCtD
Diphenhydramine—Dry mouth—Mycophenolate mofetil—psoriasis	0.000127	0.00185	CcSEcCtD
Diphenhydramine—Confusional state—Mycophenolate mofetil—psoriasis	0.000125	0.00183	CcSEcCtD
Diphenhydramine—Thrombocytopenia—Cyclosporine—psoriasis	0.000125	0.00182	CcSEcCtD
Diphenhydramine—Vertigo—Hydrocortisone—psoriasis	0.000125	0.00182	CcSEcCtD
Diphenhydramine—Dizziness—Hydroxyurea—psoriasis	0.000124	0.00181	CcSEcCtD
Diphenhydramine—Hyperhidrosis—Cyclosporine—psoriasis	0.000123	0.0018	CcSEcCtD
Diphenhydramine—Convulsion—Prednisolone—psoriasis	0.000123	0.00179	CcSEcCtD
Diphenhydramine—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000122	0.00177	CcSEcCtD
Diphenhydramine—Anorexia—Cyclosporine—psoriasis	0.000121	0.00177	CcSEcCtD
Diphenhydramine—Tachycardia—Mycophenolate mofetil—psoriasis	0.000121	0.00177	CcSEcCtD
Diphenhydramine—Convulsion—Hydrocortisone—psoriasis	0.00012	0.00175	CcSEcCtD
Diphenhydramine—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.00012	0.00175	CcSEcCtD
Diphenhydramine—Vomiting—Hydroxyurea—psoriasis	0.00012	0.00174	CcSEcCtD
Diphenhydramine—Rash—Hydroxyurea—psoriasis	0.000119	0.00173	CcSEcCtD
Diphenhydramine—Anorexia—Mycophenolate mofetil—psoriasis	0.000118	0.00173	CcSEcCtD
Diphenhydramine—Dermatitis—Hydroxyurea—psoriasis	0.000118	0.00173	CcSEcCtD
Diphenhydramine—Headache—Hydroxyurea—psoriasis	0.000118	0.00172	CcSEcCtD
Diphenhydramine—Vertigo—Triamcinolone—psoriasis	0.000117	0.00171	CcSEcCtD
Diphenhydramine—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	0.000117	0.00689	CbGpPWpGaD
Diphenhydramine—Hypotension—Mycophenolate mofetil—psoriasis	0.000116	0.00169	CcSEcCtD
Diphenhydramine—Dysuria—Methotrexate—psoriasis	0.000116	0.00169	CcSEcCtD
Diphenhydramine—Insomnia—Cyclosporine—psoriasis	0.000115	0.00168	CcSEcCtD
Diphenhydramine—Paraesthesia—Cyclosporine—psoriasis	0.000114	0.00167	CcSEcCtD
Diphenhydramine—Somnolence—Cyclosporine—psoriasis	0.000113	0.00165	CcSEcCtD
Diphenhydramine—Convulsion—Triamcinolone—psoriasis	0.000113	0.00165	CcSEcCtD
Diphenhydramine—Tachycardia—Prednisolone—psoriasis	0.000113	0.00165	CcSEcCtD
Diphenhydramine—Photosensitivity reaction—Methotrexate—psoriasis	0.000113	0.00165	CcSEcCtD
Diphenhydramine—Asthenia—Mycophenolic acid—psoriasis	0.000113	0.00165	CcSEcCtD
Diphenhydramine—Insomnia—Mycophenolate mofetil—psoriasis	0.000112	0.00164	CcSEcCtD
Diphenhydramine—Dyspepsia—Cyclosporine—psoriasis	0.000112	0.00163	CcSEcCtD
Diphenhydramine—Hyperhidrosis—Prednisolone—psoriasis	0.000112	0.00163	CcSEcCtD
Diphenhydramine—Nausea—Hydroxyurea—psoriasis	0.000112	0.00163	CcSEcCtD
Diphenhydramine—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000112	0.00163	CcSEcCtD
Diphenhydramine—Decreased appetite—Cyclosporine—psoriasis	0.000111	0.00161	CcSEcCtD
Diphenhydramine—Tachycardia—Hydrocortisone—psoriasis	0.00011	0.00161	CcSEcCtD
Diphenhydramine—Somnolence—Mycophenolate mofetil—psoriasis	0.00011	0.00161	CcSEcCtD
Diphenhydramine—Drowsiness—Methotrexate—psoriasis	0.00011	0.00161	CcSEcCtD
Diphenhydramine—Fatigue—Cyclosporine—psoriasis	0.00011	0.0016	CcSEcCtD
Diphenhydramine—Hyperhidrosis—Hydrocortisone—psoriasis	0.000109	0.0016	CcSEcCtD
Diphenhydramine—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000109	0.00644	CbGpPWpGaD
Diphenhydramine—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000109	0.00159	CcSEcCtD
Diphenhydramine—Constipation—Cyclosporine—psoriasis	0.000109	0.00159	CcSEcCtD
Diphenhydramine—Dry mouth—Triamcinolone—psoriasis	0.000109	0.00159	CcSEcCtD
Diphenhydramine—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000108	0.00157	CcSEcCtD
Diphenhydramine—Anorexia—Hydrocortisone—psoriasis	0.000108	0.00157	CcSEcCtD
Diphenhydramine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000108	0.00635	CbGpPWpGaD
Diphenhydramine—Diarrhoea—Mycophenolic acid—psoriasis	0.000108	0.00157	CcSEcCtD
Diphenhydramine—CHRM2—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	0.000107	0.00629	CbGpPWpGaD
Diphenhydramine—Vertigo—Betamethasone—psoriasis	0.000106	0.00155	CcSEcCtD
Diphenhydramine—Vertigo—Dexamethasone—psoriasis	0.000106	0.00155	CcSEcCtD
Diphenhydramine—Constipation—Mycophenolate mofetil—psoriasis	0.000106	0.00155	CcSEcCtD
Diphenhydramine—Hypotension—Hydrocortisone—psoriasis	0.000106	0.00154	CcSEcCtD
Diphenhydramine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000105	0.0062	CbGpPWpGaD
Diphenhydramine—Feeling abnormal—Cyclosporine—psoriasis	0.000105	0.00153	CcSEcCtD
Diphenhydramine—Insomnia—Prednisolone—psoriasis	0.000105	0.00153	CcSEcCtD
Diphenhydramine—Dizziness—Mycophenolic acid—psoriasis	0.000104	0.00152	CcSEcCtD
Diphenhydramine—Paraesthesia—Prednisolone—psoriasis	0.000104	0.00152	CcSEcCtD
Diphenhydramine—Tachycardia—Triamcinolone—psoriasis	0.000104	0.00152	CcSEcCtD
Diphenhydramine—Hyperhidrosis—Triamcinolone—psoriasis	0.000103	0.0015	CcSEcCtD
Diphenhydramine—Agranulocytosis—Methotrexate—psoriasis	0.000103	0.0015	CcSEcCtD
Diphenhydramine—Convulsion—Dexamethasone—psoriasis	0.000103	0.0015	CcSEcCtD
Diphenhydramine—Convulsion—Betamethasone—psoriasis	0.000103	0.0015	CcSEcCtD
Diphenhydramine—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000102	0.00149	CcSEcCtD
Diphenhydramine—Insomnia—Hydrocortisone—psoriasis	0.000102	0.00149	CcSEcCtD
Diphenhydramine—Paraesthesia—Hydrocortisone—psoriasis	0.000102	0.00148	CcSEcCtD
Diphenhydramine—Urticaria—Cyclosporine—psoriasis	0.000101	0.00148	CcSEcCtD
Diphenhydramine—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000101	0.00592	CbGpPWpGaD
Diphenhydramine—Vomiting—Mycophenolic acid—psoriasis	0.0001	0.00146	CcSEcCtD
Diphenhydramine—Dyspepsia—Hydrocortisone—psoriasis	9.96e-05	0.00145	CcSEcCtD
Diphenhydramine—Rash—Mycophenolic acid—psoriasis	9.93e-05	0.00145	CcSEcCtD
Diphenhydramine—Dermatitis—Mycophenolic acid—psoriasis	9.92e-05	0.00145	CcSEcCtD
Diphenhydramine—Urticaria—Mycophenolate mofetil—psoriasis	9.87e-05	0.00144	CcSEcCtD
Diphenhydramine—CYP2B6—Biological oxidations—CYP2S1—psoriasis	9.87e-05	0.00581	CbGpPWpGaD
Diphenhydramine—Headache—Mycophenolic acid—psoriasis	9.86e-05	0.00144	CcSEcCtD
Diphenhydramine—Decreased appetite—Hydrocortisone—psoriasis	9.84e-05	0.00143	CcSEcCtD
Diphenhydramine—CHRM2—G alpha (i) signalling events—HCAR2—psoriasis	9.79e-05	0.00577	CbGpPWpGaD
Diphenhydramine—Fatigue—Hydrocortisone—psoriasis	9.76e-05	0.00142	CcSEcCtD
Diphenhydramine—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	9.73e-05	0.00573	CbGpPWpGaD
Diphenhydramine—Vision blurred—Prednisone—psoriasis	9.72e-05	0.00142	CcSEcCtD
Diphenhydramine—Insomnia—Triamcinolone—psoriasis	9.64e-05	0.00141	CcSEcCtD
Diphenhydramine—Paraesthesia—Triamcinolone—psoriasis	9.57e-05	0.0014	CcSEcCtD
Diphenhydramine—Feeling abnormal—Prednisolone—psoriasis	9.55e-05	0.00139	CcSEcCtD
Diphenhydramine—Agitation—Prednisone—psoriasis	9.48e-05	0.00138	CcSEcCtD
Diphenhydramine—Thrombocytopenia—Betamethasone—psoriasis	9.47e-05	0.00138	CcSEcCtD
Diphenhydramine—Thrombocytopenia—Dexamethasone—psoriasis	9.47e-05	0.00138	CcSEcCtD
Diphenhydramine—Tachycardia—Dexamethasone—psoriasis	9.44e-05	0.00138	CcSEcCtD
Diphenhydramine—Tachycardia—Betamethasone—psoriasis	9.44e-05	0.00138	CcSEcCtD
Diphenhydramine—Dyspepsia—Triamcinolone—psoriasis	9.38e-05	0.00137	CcSEcCtD
Diphenhydramine—Nausea—Mycophenolic acid—psoriasis	9.35e-05	0.00136	CcSEcCtD
Diphenhydramine—Hyperhidrosis—Dexamethasone—psoriasis	9.35e-05	0.00136	CcSEcCtD
Diphenhydramine—Hyperhidrosis—Betamethasone—psoriasis	9.35e-05	0.00136	CcSEcCtD
Diphenhydramine—Feeling abnormal—Hydrocortisone—psoriasis	9.33e-05	0.00136	CcSEcCtD
Diphenhydramine—Vertigo—Prednisone—psoriasis	9.27e-05	0.00135	CcSEcCtD
Diphenhydramine—Tinnitus—Methotrexate—psoriasis	9.24e-05	0.00135	CcSEcCtD
Diphenhydramine—HRH1—IL-4 Signaling Pathway—SOCS1—psoriasis	9.22e-05	0.00544	CbGpPWpGaD
Diphenhydramine—Anorexia—Dexamethasone—psoriasis	9.22e-05	0.00134	CcSEcCtD
Diphenhydramine—Anorexia—Betamethasone—psoriasis	9.22e-05	0.00134	CcSEcCtD
Diphenhydramine—Urticaria—Prednisolone—psoriasis	9.21e-05	0.00134	CcSEcCtD
Diphenhydramine—Fatigue—Triamcinolone—psoriasis	9.19e-05	0.00134	CcSEcCtD
Diphenhydramine—Asthenia—Cyclosporine—psoriasis	9.14e-05	0.00133	CcSEcCtD
Diphenhydramine—Hypotension—Dexamethasone—psoriasis	9.04e-05	0.00132	CcSEcCtD
Diphenhydramine—Hypotension—Betamethasone—psoriasis	9.04e-05	0.00132	CcSEcCtD
Diphenhydramine—Urticaria—Hydrocortisone—psoriasis	8.99e-05	0.00131	CcSEcCtD
Diphenhydramine—Convulsion—Prednisone—psoriasis	8.94e-05	0.0013	CcSEcCtD
Diphenhydramine—Asthenia—Mycophenolate mofetil—psoriasis	8.91e-05	0.0013	CcSEcCtD
Diphenhydramine—Chills—Methotrexate—psoriasis	8.89e-05	0.0013	CcSEcCtD
Diphenhydramine—Feeling abnormal—Triamcinolone—psoriasis	8.78e-05	0.00128	CcSEcCtD
Diphenhydramine—Insomnia—Dexamethasone—psoriasis	8.75e-05	0.00128	CcSEcCtD
Diphenhydramine—Insomnia—Betamethasone—psoriasis	8.75e-05	0.00128	CcSEcCtD
Diphenhydramine—Diarrhoea—Cyclosporine—psoriasis	8.71e-05	0.00127	CcSEcCtD
Diphenhydramine—Paraesthesia—Betamethasone—psoriasis	8.68e-05	0.00127	CcSEcCtD
Diphenhydramine—Paraesthesia—Dexamethasone—psoriasis	8.68e-05	0.00127	CcSEcCtD
Diphenhydramine—CYP2C18—FOXA1 transcription factor network—JUN—psoriasis	8.61e-05	0.00508	CbGpPWpGaD
Diphenhydramine—Dyspepsia—Betamethasone—psoriasis	8.51e-05	0.00124	CcSEcCtD
Diphenhydramine—Dyspepsia—Dexamethasone—psoriasis	8.51e-05	0.00124	CcSEcCtD
Diphenhydramine—Diarrhoea—Mycophenolate mofetil—psoriasis	8.5e-05	0.00124	CcSEcCtD
Diphenhydramine—Urticaria—Triamcinolone—psoriasis	8.47e-05	0.00123	CcSEcCtD
Diphenhydramine—Dizziness—Cyclosporine—psoriasis	8.42e-05	0.00123	CcSEcCtD
Diphenhydramine—Decreased appetite—Betamethasone—psoriasis	8.41e-05	0.00123	CcSEcCtD
Diphenhydramine—Decreased appetite—Dexamethasone—psoriasis	8.41e-05	0.00123	CcSEcCtD
Diphenhydramine—Fatigue—Dexamethasone—psoriasis	8.34e-05	0.00122	CcSEcCtD
Diphenhydramine—Fatigue—Betamethasone—psoriasis	8.34e-05	0.00122	CcSEcCtD
Diphenhydramine—Tachycardia—Prednisone—psoriasis	8.22e-05	0.0012	CcSEcCtD
Diphenhydramine—Dizziness—Mycophenolate mofetil—psoriasis	8.22e-05	0.0012	CcSEcCtD
Diphenhydramine—Hyperhidrosis—Prednisone—psoriasis	8.14e-05	0.00119	CcSEcCtD
Diphenhydramine—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	8.14e-05	0.00479	CbGpPWpGaD
Diphenhydramine—Vision blurred—Methotrexate—psoriasis	8.13e-05	0.00119	CcSEcCtD
Diphenhydramine—Asthenia—Hydrocortisone—psoriasis	8.12e-05	0.00118	CcSEcCtD
Diphenhydramine—Vomiting—Cyclosporine—psoriasis	8.1e-05	0.00118	CcSEcCtD
Diphenhydramine—HRH1—IL-4 Signaling Pathway—IL4—psoriasis	8.05e-05	0.00474	CbGpPWpGaD
Diphenhydramine—Rash—Cyclosporine—psoriasis	8.03e-05	0.00117	CcSEcCtD
Diphenhydramine—Anorexia—Prednisone—psoriasis	8.03e-05	0.00117	CcSEcCtD
Diphenhydramine—Dermatitis—Cyclosporine—psoriasis	8.02e-05	0.00117	CcSEcCtD
Diphenhydramine—Headache—Cyclosporine—psoriasis	7.98e-05	0.00116	CcSEcCtD
Diphenhydramine—Feeling abnormal—Dexamethasone—psoriasis	7.97e-05	0.00116	CcSEcCtD
Diphenhydramine—Feeling abnormal—Betamethasone—psoriasis	7.97e-05	0.00116	CcSEcCtD
Diphenhydramine—HRH1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	7.91e-05	0.00466	CbGpPWpGaD
Diphenhydramine—Vomiting—Mycophenolate mofetil—psoriasis	7.9e-05	0.00115	CcSEcCtD
Diphenhydramine—Rash—Mycophenolate mofetil—psoriasis	7.83e-05	0.00114	CcSEcCtD
Diphenhydramine—Dermatitis—Mycophenolate mofetil—psoriasis	7.83e-05	0.00114	CcSEcCtD
Diphenhydramine—SLC22A5—SLC-mediated transmembrane transport—CP—psoriasis	7.79e-05	0.00459	CbGpPWpGaD
Diphenhydramine—Headache—Mycophenolate mofetil—psoriasis	7.78e-05	0.00113	CcSEcCtD
Diphenhydramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	7.78e-05	0.00458	CbGpPWpGaD
Diphenhydramine—Vertigo—Methotrexate—psoriasis	7.75e-05	0.00113	CcSEcCtD
Diphenhydramine—Diarrhoea—Hydrocortisone—psoriasis	7.74e-05	0.00113	CcSEcCtD
Diphenhydramine—Urticaria—Dexamethasone—psoriasis	7.68e-05	0.00112	CcSEcCtD
Diphenhydramine—Urticaria—Betamethasone—psoriasis	7.68e-05	0.00112	CcSEcCtD
Diphenhydramine—Dizziness—Prednisolone—psoriasis	7.66e-05	0.00112	CcSEcCtD
Diphenhydramine—Asthenia—Triamcinolone—psoriasis	7.65e-05	0.00112	CcSEcCtD
Diphenhydramine—Insomnia—Prednisone—psoriasis	7.62e-05	0.00111	CcSEcCtD
Diphenhydramine—Nausea—Cyclosporine—psoriasis	7.56e-05	0.0011	CcSEcCtD
Diphenhydramine—Paraesthesia—Prednisone—psoriasis	7.56e-05	0.0011	CcSEcCtD
Diphenhydramine—Dizziness—Hydrocortisone—psoriasis	7.48e-05	0.00109	CcSEcCtD
Diphenhydramine—Convulsion—Methotrexate—psoriasis	7.47e-05	0.00109	CcSEcCtD
Diphenhydramine—CYP2C19—Biological oxidations—CYP2S1—psoriasis	7.46e-05	0.00439	CbGpPWpGaD
Diphenhydramine—Dyspepsia—Prednisone—psoriasis	7.41e-05	0.00108	CcSEcCtD
Diphenhydramine—Nausea—Mycophenolate mofetil—psoriasis	7.38e-05	0.00108	CcSEcCtD
Diphenhydramine—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	7.35e-05	0.00433	CbGpPWpGaD
Diphenhydramine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.34e-05	0.00432	CbGpPWpGaD
Diphenhydramine—Decreased appetite—Prednisone—psoriasis	7.32e-05	0.00107	CcSEcCtD
Diphenhydramine—Rash—Prednisolone—psoriasis	7.31e-05	0.00107	CcSEcCtD
Diphenhydramine—Dermatitis—Prednisolone—psoriasis	7.3e-05	0.00106	CcSEcCtD
Diphenhydramine—Fatigue—Prednisone—psoriasis	7.26e-05	0.00106	CcSEcCtD
Diphenhydramine—Headache—Prednisolone—psoriasis	7.26e-05	0.00106	CcSEcCtD
Diphenhydramine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.25e-05	0.00427	CbGpPWpGaD
Diphenhydramine—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	7.23e-05	0.00426	CbGpPWpGaD
Diphenhydramine—Constipation—Prednisone—psoriasis	7.2e-05	0.00105	CcSEcCtD
Diphenhydramine—Vomiting—Hydrocortisone—psoriasis	7.2e-05	0.00105	CcSEcCtD
Diphenhydramine—Rash—Hydrocortisone—psoriasis	7.14e-05	0.00104	CcSEcCtD
Diphenhydramine—Dermatitis—Hydrocortisone—psoriasis	7.13e-05	0.00104	CcSEcCtD
Diphenhydramine—Confusional state—Methotrexate—psoriasis	7.1e-05	0.00103	CcSEcCtD
Diphenhydramine—Headache—Hydrocortisone—psoriasis	7.09e-05	0.00103	CcSEcCtD
Diphenhydramine—CHRM2—SIDS Susceptibility Pathways—RUNX3—psoriasis	7.05e-05	0.00416	CbGpPWpGaD
Diphenhydramine—Dizziness—Triamcinolone—psoriasis	7.05e-05	0.00103	CcSEcCtD
Diphenhydramine—Feeling abnormal—Prednisone—psoriasis	6.94e-05	0.00101	CcSEcCtD
Diphenhydramine—Asthenia—Dexamethasone—psoriasis	6.94e-05	0.00101	CcSEcCtD
Diphenhydramine—Asthenia—Betamethasone—psoriasis	6.94e-05	0.00101	CcSEcCtD
Diphenhydramine—Thrombocytopenia—Methotrexate—psoriasis	6.89e-05	0.001	CcSEcCtD
Diphenhydramine—Nausea—Prednisolone—psoriasis	6.88e-05	0.001	CcSEcCtD
Diphenhydramine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	6.86e-05	0.00404	CbGpPWpGaD
Diphenhydramine—Hyperhidrosis—Methotrexate—psoriasis	6.8e-05	0.000992	CcSEcCtD
Diphenhydramine—CYP2C9—Biological oxidations—CYP2S1—psoriasis	6.8e-05	0.00401	CbGpPWpGaD
Diphenhydramine—Vomiting—Triamcinolone—psoriasis	6.78e-05	0.000988	CcSEcCtD
Diphenhydramine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	6.76e-05	0.00399	CbGpPWpGaD
Diphenhydramine—Nausea—Hydrocortisone—psoriasis	6.72e-05	0.00098	CcSEcCtD
Diphenhydramine—Rash—Triamcinolone—psoriasis	6.72e-05	0.00098	CcSEcCtD
Diphenhydramine—Dermatitis—Triamcinolone—psoriasis	6.71e-05	0.000979	CcSEcCtD
Diphenhydramine—Anorexia—Methotrexate—psoriasis	6.71e-05	0.000978	CcSEcCtD
Diphenhydramine—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	6.71e-05	0.00395	CbGpPWpGaD
Diphenhydramine—Urticaria—Prednisone—psoriasis	6.69e-05	0.000976	CcSEcCtD
Diphenhydramine—Headache—Triamcinolone—psoriasis	6.68e-05	0.000974	CcSEcCtD
Diphenhydramine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	6.65e-05	0.00392	CbGpPWpGaD
Diphenhydramine—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	6.64e-05	0.00391	CbGpPWpGaD
Diphenhydramine—Diarrhoea—Betamethasone—psoriasis	6.62e-05	0.000965	CcSEcCtD
Diphenhydramine—Diarrhoea—Dexamethasone—psoriasis	6.62e-05	0.000965	CcSEcCtD
Diphenhydramine—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	6.61e-05	0.0039	CbGpPWpGaD
Diphenhydramine—Hypotension—Methotrexate—psoriasis	6.58e-05	0.000959	CcSEcCtD
Diphenhydramine—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	6.57e-05	0.00387	CbGpPWpGaD
Diphenhydramine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	6.47e-05	0.00381	CbGpPWpGaD
Diphenhydramine—Dizziness—Dexamethasone—psoriasis	6.39e-05	0.000932	CcSEcCtD
Diphenhydramine—Dizziness—Betamethasone—psoriasis	6.39e-05	0.000932	CcSEcCtD
Diphenhydramine—Insomnia—Methotrexate—psoriasis	6.37e-05	0.000928	CcSEcCtD
Diphenhydramine—HRH1—IL-4 Signaling Pathway—NFKBIA—psoriasis	6.34e-05	0.00374	CbGpPWpGaD
Diphenhydramine—Nausea—Triamcinolone—psoriasis	6.33e-05	0.000923	CcSEcCtD
Diphenhydramine—Paraesthesia—Methotrexate—psoriasis	6.32e-05	0.000922	CcSEcCtD
Diphenhydramine—Somnolence—Methotrexate—psoriasis	6.26e-05	0.000912	CcSEcCtD
Diphenhydramine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	6.2e-05	0.00365	CbGpPWpGaD
Diphenhydramine—Dyspepsia—Methotrexate—psoriasis	6.2e-05	0.000903	CcSEcCtD
Diphenhydramine—Vomiting—Betamethasone—psoriasis	6.15e-05	0.000897	CcSEcCtD
Diphenhydramine—Vomiting—Dexamethasone—psoriasis	6.15e-05	0.000897	CcSEcCtD
Diphenhydramine—Decreased appetite—Methotrexate—psoriasis	6.12e-05	0.000892	CcSEcCtD
Diphenhydramine—Rash—Dexamethasone—psoriasis	6.1e-05	0.000889	CcSEcCtD
Diphenhydramine—Rash—Betamethasone—psoriasis	6.1e-05	0.000889	CcSEcCtD
Diphenhydramine—Dermatitis—Dexamethasone—psoriasis	6.09e-05	0.000888	CcSEcCtD
Diphenhydramine—Dermatitis—Betamethasone—psoriasis	6.09e-05	0.000888	CcSEcCtD
Diphenhydramine—Fatigue—Methotrexate—psoriasis	6.07e-05	0.000885	CcSEcCtD
Diphenhydramine—Headache—Dexamethasone—psoriasis	6.06e-05	0.000883	CcSEcCtD
Diphenhydramine—Headache—Betamethasone—psoriasis	6.06e-05	0.000883	CcSEcCtD
Diphenhydramine—Asthenia—Prednisone—psoriasis	6.04e-05	0.000881	CcSEcCtD
Diphenhydramine—HRH1—GPCR ligand binding—HCAR2—psoriasis	6.02e-05	0.00355	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR ligand binding—HCAR2—psoriasis	5.93e-05	0.00349	CbGpPWpGaD
Diphenhydramine—CYP1A2—Biological oxidations—CYP2S1—psoriasis	5.81e-05	0.00342	CbGpPWpGaD
Diphenhydramine—Feeling abnormal—Methotrexate—psoriasis	5.8e-05	0.000846	CcSEcCtD
Diphenhydramine—Diarrhoea—Prednisone—psoriasis	5.76e-05	0.00084	CcSEcCtD
Diphenhydramine—Nausea—Dexamethasone—psoriasis	5.74e-05	0.000838	CcSEcCtD
Diphenhydramine—Nausea—Betamethasone—psoriasis	5.74e-05	0.000838	CcSEcCtD
Diphenhydramine—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	5.73e-05	0.00338	CbGpPWpGaD
Diphenhydramine—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	5.72e-05	0.00337	CbGpPWpGaD
Diphenhydramine—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	5.63e-05	0.00332	CbGpPWpGaD
Diphenhydramine—Urticaria—Methotrexate—psoriasis	5.59e-05	0.000815	CcSEcCtD
Diphenhydramine—CHRM2—SIDS Susceptibility Pathways—IL13—psoriasis	5.57e-05	0.00328	CbGpPWpGaD
Diphenhydramine—Dizziness—Prednisone—psoriasis	5.57e-05	0.000812	CcSEcCtD
Diphenhydramine—Vomiting—Prednisone—psoriasis	5.35e-05	0.000781	CcSEcCtD
Diphenhydramine—Rash—Prednisone—psoriasis	5.31e-05	0.000774	CcSEcCtD
Diphenhydramine—Dermatitis—Prednisone—psoriasis	5.3e-05	0.000774	CcSEcCtD
Diphenhydramine—Headache—Prednisone—psoriasis	5.28e-05	0.000769	CcSEcCtD
Diphenhydramine—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	5.27e-05	0.00311	CbGpPWpGaD
Diphenhydramine—HRH1—IL-4 Signaling Pathway—TYK2—psoriasis	5.2e-05	0.00306	CbGpPWpGaD
Diphenhydramine—CHRM2—G alpha (i) signalling events—CCL20—psoriasis	5.08e-05	0.00299	CbGpPWpGaD
Diphenhydramine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.06e-05	0.00298	CbGpPWpGaD
Diphenhydramine—Asthenia—Methotrexate—psoriasis	5.05e-05	0.000736	CcSEcCtD
Diphenhydramine—CYP1A2—Tryptophan metabolism—CAT—psoriasis	5.01e-05	0.00295	CbGpPWpGaD
Diphenhydramine—Nausea—Prednisone—psoriasis	5e-05	0.000729	CcSEcCtD
Diphenhydramine—SLC22A2—SLC-mediated transmembrane transport—CP—psoriasis	4.9e-05	0.00289	CbGpPWpGaD
Diphenhydramine—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	4.85e-05	0.00286	CbGpPWpGaD
Diphenhydramine—Diarrhoea—Methotrexate—psoriasis	4.82e-05	0.000702	CcSEcCtD
Diphenhydramine—Dizziness—Methotrexate—psoriasis	4.65e-05	0.000679	CcSEcCtD
Diphenhydramine—SLC22A1—SLC-mediated transmembrane transport—CP—psoriasis	4.57e-05	0.00269	CbGpPWpGaD
Diphenhydramine—Vomiting—Methotrexate—psoriasis	4.47e-05	0.000653	CcSEcCtD
Diphenhydramine—Rash—Methotrexate—psoriasis	4.44e-05	0.000647	CcSEcCtD
Diphenhydramine—Dermatitis—Methotrexate—psoriasis	4.43e-05	0.000646	CcSEcCtD
Diphenhydramine—Headache—Methotrexate—psoriasis	4.41e-05	0.000643	CcSEcCtD
Diphenhydramine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.32e-05	0.00255	CbGpPWpGaD
Diphenhydramine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	4.3e-05	0.00253	CbGpPWpGaD
Diphenhydramine—Nausea—Methotrexate—psoriasis	4.18e-05	0.00061	CcSEcCtD
Diphenhydramine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	4.11e-05	0.00242	CbGpPWpGaD
Diphenhydramine—HRH1—IL-4 Signaling Pathway—NFKB1—psoriasis	4.05e-05	0.00239	CbGpPWpGaD
Diphenhydramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	4.04e-05	0.00238	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—NDUFA5—psoriasis	4.04e-05	0.00238	CbGpPWpGaD
Diphenhydramine—SLC22A5—Transmembrane transport of small molecules—CP—psoriasis	3.96e-05	0.00233	CbGpPWpGaD
Diphenhydramine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	3.95e-05	0.00233	CbGpPWpGaD
Diphenhydramine—SLC22A5—Transmembrane transport of small molecules—CARM1—psoriasis	3.78e-05	0.00222	CbGpPWpGaD
Diphenhydramine—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	3.69e-05	0.00217	CbGpPWpGaD
Diphenhydramine—HRH1—IL-4 Signaling Pathway—STAT3—psoriasis	3.64e-05	0.00214	CbGpPWpGaD
Diphenhydramine—CHRM2—SIDS Susceptibility Pathways—IL10—psoriasis	3.48e-05	0.00205	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—CYP2S1—psoriasis	3.43e-05	0.00202	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR downstream signaling—HCAR2—psoriasis	3.4e-05	0.002	CbGpPWpGaD
Diphenhydramine—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	3.35e-05	0.00197	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR downstream signaling—HCAR2—psoriasis	3.35e-05	0.00197	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR ligand binding—CCL20—psoriasis	3.13e-05	0.00184	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—HCAR2—psoriasis	3.09e-05	0.00182	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR ligand binding—CCL20—psoriasis	3.08e-05	0.00181	CbGpPWpGaD
Diphenhydramine—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	3.07e-05	0.00181	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—HCAR2—psoriasis	3.04e-05	0.00179	CbGpPWpGaD
Diphenhydramine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	2.78e-05	0.00164	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—NDUFA5—psoriasis	2.68e-05	0.00158	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—NDUFA5—psoriasis	2.6e-05	0.00153	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—NDUFA5—psoriasis	2.5e-05	0.00147	CbGpPWpGaD
Diphenhydramine—SLC22A2—Transmembrane transport of small molecules—CP—psoriasis	2.49e-05	0.00147	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.43e-05	0.00143	CbGpPWpGaD
Diphenhydramine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	2.41e-05	0.00142	CbGpPWpGaD
Diphenhydramine—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	2.39e-05	0.00141	CbGpPWpGaD
Diphenhydramine—SLC22A2—Transmembrane transport of small molecules—CARM1—psoriasis	2.38e-05	0.0014	CbGpPWpGaD
Diphenhydramine—SLC22A1—Transmembrane transport of small molecules—CP—psoriasis	2.32e-05	0.00137	CbGpPWpGaD
Diphenhydramine—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	2.32e-05	0.00136	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—CYP2S1—psoriasis	2.28e-05	0.00134	CbGpPWpGaD
Diphenhydramine—SLC22A1—Transmembrane transport of small molecules—CARM1—psoriasis	2.21e-05	0.0013	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—CYP2S1—psoriasis	2.21e-05	0.0013	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—CYP2S1—psoriasis	2.12e-05	0.00125	CbGpPWpGaD
Diphenhydramine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	2.1e-05	0.00124	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—NDUFA5—psoriasis	1.98e-05	0.00117	CbGpPWpGaD
Diphenhydramine—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	1.93e-05	0.00113	CbGpPWpGaD
Diphenhydramine—CHRM2—SIDS Susceptibility Pathways—CXCL8—psoriasis	1.91e-05	0.00112	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—HCAR2—psoriasis	1.83e-05	0.00108	CbGpPWpGaD
Diphenhydramine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	1.8e-05	0.00106	CbGpPWpGaD
Diphenhydramine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	1.8e-05	0.00106	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—HCAR2—psoriasis	1.8e-05	0.00106	CbGpPWpGaD
Diphenhydramine—CHRM2—SIDS Susceptibility Pathways—JUN—psoriasis	1.77e-05	0.00104	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR downstream signaling—CCL20—psoriasis	1.77e-05	0.00104	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR downstream signaling—CCL20—psoriasis	1.74e-05	0.00102	CbGpPWpGaD
Diphenhydramine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	1.72e-05	0.00101	CbGpPWpGaD
Diphenhydramine—CHRM2—SIDS Susceptibility Pathways—NFKB1—psoriasis	1.7e-05	0.001	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—CYP2S1—psoriasis	1.69e-05	0.000994	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—CARM1—psoriasis	1.68e-05	0.000988	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—CCL20—psoriasis	1.61e-05	0.000946	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—TAGAP—psoriasis	1.58e-05	0.000933	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—CCL20—psoriasis	1.58e-05	0.000931	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—TAGAP—psoriasis	1.56e-05	0.000918	CbGpPWpGaD
Diphenhydramine—CHRM2—SIDS Susceptibility Pathways—VEGFA—psoriasis	1.55e-05	0.000912	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—NDUFA5—psoriasis	1.5e-05	0.000884	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.4e-05	0.000824	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—NDUFA5—psoriasis	1.38e-05	0.000813	CbGpPWpGaD
Diphenhydramine—CHRM2—G alpha (i) signalling events—CXCL8—psoriasis	1.37e-05	0.000809	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—NDUFA5—psoriasis	1.37e-05	0.000806	CbGpPWpGaD
Diphenhydramine—CHRM2—SIDS Susceptibility Pathways—TNF—psoriasis	1.33e-05	0.000781	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—CYP2S1—psoriasis	1.28e-05	0.000751	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.28e-05	0.000751	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—CYP2S1—psoriasis	1.17e-05	0.000691	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—NDUFA5—psoriasis	1.17e-05	0.000689	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—CYP2S1—psoriasis	1.16e-05	0.000685	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.16e-05	0.000683	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—CARM1—psoriasis	1.11e-05	0.000656	CbGpPWpGaD
Diphenhydramine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.11e-05	0.000653	CbGpPWpGaD
Diphenhydramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.09e-05	0.000643	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.09e-05	0.000642	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—CARM1—psoriasis	1.08e-05	0.000636	CbGpPWpGaD
Diphenhydramine—CHRM2—SIDS Susceptibility Pathways—IL6—psoriasis	1.07e-05	0.000631	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—CARM1—psoriasis	1.04e-05	0.000611	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—CAT—psoriasis	1.03e-05	0.000608	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.01e-05	0.000595	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—CYP2S1—psoriasis	9.94e-06	0.000585	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—CCL20—psoriasis	9.48e-06	0.000559	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—CCL20—psoriasis	9.33e-06	0.00055	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR ligand binding—CXCL8—psoriasis	8.45e-06	0.000498	CbGpPWpGaD
Diphenhydramine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	8.41e-06	0.000496	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR ligand binding—CXCL8—psoriasis	8.31e-06	0.00049	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—CARM1—psoriasis	8.24e-06	0.000486	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—APOE—psoriasis	8.01e-06	0.000472	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—PPARG—psoriasis	6.98e-06	0.000411	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—CAT—psoriasis	6.84e-06	0.000403	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.68e-06	0.000394	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—CAT—psoriasis	6.64e-06	0.000391	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—CAT—psoriasis	6.38e-06	0.000376	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—CARM1—psoriasis	6.23e-06	0.000367	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.09e-06	0.000359	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.82e-06	0.000343	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—CARM1—psoriasis	5.73e-06	0.000338	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—CARM1—psoriasis	5.68e-06	0.000335	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—APOE—psoriasis	5.32e-06	0.000313	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.31e-06	0.000313	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—SOCS1—psoriasis	5.22e-06	0.000308	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.21e-06	0.000307	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—APOE—psoriasis	5.16e-06	0.000304	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—SOCS1—psoriasis	5.14e-06	0.000303	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—CAT—psoriasis	5.07e-06	0.000299	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—TYK2—psoriasis	4.98e-06	0.000293	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—APOE—psoriasis	4.96e-06	0.000292	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—TYK2—psoriasis	4.9e-06	0.000289	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—CARM1—psoriasis	4.85e-06	0.000286	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR downstream signaling—CXCL8—psoriasis	4.77e-06	0.000281	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR downstream signaling—CXCL8—psoriasis	4.7e-06	0.000277	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—PPARG—psoriasis	4.63e-06	0.000273	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.54e-06	0.000267	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—PPARG—psoriasis	4.5e-06	0.000265	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—CXCL8—psoriasis	4.33e-06	0.000255	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—PPARG—psoriasis	4.32e-06	0.000254	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—CXCL8—psoriasis	4.27e-06	0.000251	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—APOE—psoriasis	3.94e-06	0.000232	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—APOE—psoriasis	3.85e-06	0.000227	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—LEP—psoriasis	3.85e-06	0.000227	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—CAT—psoriasis	3.83e-06	0.000226	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—LEP—psoriasis	3.79e-06	0.000223	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—APOE—psoriasis	3.79e-06	0.000223	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—NFKBIA—psoriasis	3.59e-06	0.000212	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—NFKBIA—psoriasis	3.53e-06	0.000208	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—CAT—psoriasis	3.52e-06	0.000208	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—CAT—psoriasis	3.49e-06	0.000206	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—PPARG—psoriasis	3.43e-06	0.000202	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—CAT—psoriasis	2.98e-06	0.000176	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—APOE—psoriasis	2.98e-06	0.000175	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—TYK2—psoriasis	2.94e-06	0.000173	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—TYK2—psoriasis	2.89e-06	0.00017	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—APOE—psoriasis	2.74e-06	0.000161	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—APOE—psoriasis	2.71e-06	0.00016	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—PPARG—psoriasis	2.59e-06	0.000153	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—CXCL8—psoriasis	2.56e-06	0.000151	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—CXCL8—psoriasis	2.52e-06	0.000148	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—IL6—psoriasis	2.43e-06	0.000143	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—IL6—psoriasis	2.4e-06	0.000141	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—PPARG—psoriasis	2.38e-06	0.00014	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—JUN—psoriasis	2.38e-06	0.00014	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—PPARG—psoriasis	2.36e-06	0.000139	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—JUN—psoriasis	2.34e-06	0.000138	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—APOE—psoriasis	2.32e-06	0.000137	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—NFKB1—psoriasis	2.29e-06	0.000135	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—NFKB1—psoriasis	2.25e-06	0.000133	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—VEGFA—psoriasis	2.08e-06	0.000123	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—STAT3—psoriasis	2.06e-06	0.000121	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—VEGFA—psoriasis	2.05e-06	0.000121	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—STAT3—psoriasis	2.03e-06	0.000119	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—PPARG—psoriasis	2.02e-06	0.000119	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—TP53—psoriasis	1.57e-06	9.26e-05	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—TP53—psoriasis	1.55e-06	9.11e-05	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—IL6—psoriasis	1.44e-06	8.47e-05	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—IL6—psoriasis	1.42e-06	8.34e-05	CbGpPWpGaD
